Anti-Vam6/Vps39-like protein VPS39 Antibody

Boster Bio Anti-Vam6/Vps39-like protein VPS39 Antibody (Catalog # A05711) . Tested in ELISA, WB, IHC-P, IF applications. This antibody reacts with Human, Mouse, Rat.

Product Specifications

Background

VPS39 is the mammalian homolog of the yeast vacuolar protein VAM6, that in mammals, promotes lysosome clustering and fusion in vivo. VPS39 is also thought to modulate the TGF-beta response by coupling the TGF-beta receptor complex to the Smad pathway. Similar to the related protein TRAP1, the VPS39 protein is essential for early embryonic development, with mice lacking VPS39 dying at or before E6.5.

Synonyms

TLP, VAM6, hVam6p, KIAA0770, TLP, TRAP1-like protein

Gene Name

VPS39

UniProt

Q96JC1

Host

Rabbit

Reactivity

Human, Mouse, Rat

Cross Reactivity

At least four isoforms of VPS39 are known to exist; this antibody will detect all four. VPS39 antibody is predicted not to cross-react with TRAP1.

Immunogen

VPS39 antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of human VPS39. The immunogen is located within amino acids 710 - 760 of VPS39.

Clonality

Polyclonal

Tissue Specificity

Widely expressed, with highest levels in heart, skeletal muscle, kidney, pancreas, brain, placenta and spleen.

Applications

ELISA, WB, IHC-P, IF

Field of Research

Stem Cells

Purification

VPS39 Antibody is affinity chromatography purified via peptide column.

Concentration

1 mg/mL

Form

Liquid

Function

Regulator of TGF-beta/activin signaling, inhibiting SMAD3- and activating SMAD2-dependent transcription. Acts by interfering with SMAD3/SMAD4 complex formation, this would lead to inhibition of SMAD3-dependent transcription and relieve SMAD3 inhibition of SMAD2-dependent promoters, thus increasing SMAD2- dependent transcription. Does not affect TGF-beta-induced SMAD2 or SMAD3 phosphorylation, nor SMAD2/SMAD4 complex formation.

Molecular Weight

101809 MW

Shipping Conditions

Available

Storage Conditions

VPS39 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.